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Research
Exposure to inorganic arsenic (iAs) from water, 
food, and ambient air is widespread (Franklin 
et al. 2008; Gilbert-Diamond et al. 2011; 
Nordstrom 2002). Humans metabolize iAs 
(arsenate and arsenite) to methylated com-
pounds [predominantly monomethyl arsonate 
(MMA) and dimethylarsinate (DMA)], which 
are largely excreted in urine together with iAs 
(Cullen and Reimer 1989; Naranmandura 
et al. 2006; Vahter 2002). In human popu-
lations, the average distribution of arsenic 
metabo lites in urine is approximately 10–30% 
iAs, approximately 10–20% MMA, and 
approximately 60–80% DMA (Chiou et al. 
1997; Gamble et al. 2005; Gomez-Rubio et al. 
2012; Hopenhayn-Rich et al. 1996b; Vahter 
2000). However, substantial inter individual 
variation is found in the distribution of urine 
arsenic metabolites. Understanding the deter-
minants of arsenic metabolism is important 
because differences in arsenic methylation 
patterns in urine have been associated with 
differential risks of skin lesions, cancer, and 
cardiovascular disease in several populations 
exposed to arsenic in drinking water (Chen 
et al. 2003; Del Razo et al. 1997; Hsueh et al. 
1997; Kile et al. 2011; Steinmaus et al. 2006; 
Wu et al. 2006; Yu et al. 2000).
Polymorphisms in arsenic (III) methyl-
transferase (AS3MT) have been consistently 
associated with urine arsenic methylation pat-
terns in populations from Argentina (Schlawicke 
et al. 2007, 2009), Chile (Hernandez et al. 
2008), Mexico (Gomez-Rubio et al. 2010; 
Meza et al. 2005), and Central Europe 
(Lindberg et al. 2007). Variation near the 
AS3MT gene has also been recently associated 
with arsenic metabolism in a genome-wide 
association study from Bangladesh (Pierce 
et al. 2012). Functional studies have confirmed 
the relevance of AS3MT in the methylation of 
arsenic (Chen et al. 2011; Drobna et al. 2006; 
Thomas et al. 2004; Wood et al. 2006). Those 
studies, however, also suggest that other genes, 
in addition to non genetic factors, may contrib-
ute to arsenic methylation and distribution in 
human tissues, although the genes involved 
remain largely unknown. Genome-wide 
genetic approaches may contribute to the dis-
covery of genes related to variation in urine 
arsenic metabolites. Moreover, while arsenic 
metabolism shows evidence for familial aggre-
gation (Chung et al. 2002), the heritability 
of urine arsenic methylation patterns has not 
been evaluated.
The Strong Heart Study (SHS) is a 
population-based prospective cohort study 
funded by the National Heart, Lung, and 
Blood Institute (NHLBI) to evaluate cardio-
vascular disease and its risk factors, including 
genetic and environmental determinants, in 
13 U.S. American Indian communities from 
Arizona, Oklahoma, and North and South 
Dakota (Lee et al. 1990). Some of these com-
munities are known to be exposed to arsenic 
in drinking water (Navas-Acien et al. 2009). 
In this study, we first evaluated the heritabil-
ity of urine arsenic methylation patterns in 
SHS participants who had at least one relative 
within the cohort. In a subset of the popula-
tion with genome-wide short tandem repeat 
(STR) markers available, we conducted a 
preliminary study to evaluate the presence of 
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Background: Arsenic (III) methyltransferase (AS3MT) has been related to urine arsenic metabolites 
in association studies. Other genes might also play roles in arsenic metabolism and excretion.
oBjective: We evaluated genetic determinants of urine arsenic metabolites in American Indian 
adults from the Strong Heart Study (SHS).
Methods: We evaluated heritability of urine arsenic metabolites [percent inorganic arsenic (%iAs), 
percent monomethylarsonate (%MMA), and percent dimethylarsinate (%DMA)] in 2,907 SHS 
participants with urine arsenic measurements and at least one relative within the cohort. We 
conducted a preliminary linkage analy sis in a subset of 487 participants with available genotypes 
on approximately 400 short tandem repeat markers using a general pedigree variance component 
approach for localizing quantitative trait loci (QTL).
results: The medians (interquartile ranges) for %iAs, %MMA, and %DMA were 7.7% 
(5.4–10.7%), 13.6% (10.5–17.1%), and 78.4% (72.5–83.1%), respectively. The estimated herita-
bility was 53% for %iAs, 50% for %MMA, and 59% for %DMA. After adjustment for sex, age, 
smoking, body mass index, alcohol consumption, region, and total urine arsenic concentrations, 
LOD [logarithm (to the base of 10) of the odds] scores indicated suggestive evidence for genetic link-
age with QTLs influencing urine arsenic metabolites on chromosomes 5 (LOD = 2.03 for %iAs), 
9 (LOD = 2.05 for %iAs and 2.10 for %MMA), and 11 (LOD = 1.94 for %iAs). A peak for %DMA 
on chromosome 10 within 2 Mb of AS3MT had an LOD of 1.80.
conclusions: This population-based family study in American Indian communities supports a 
genetic contribution to variation in the distribution of arsenic metabolites in urine and, potentially, 
the involvement of genes other than AS3MT.
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genetic loci associated with the distribution 
of urine arsenic metabolites by conducting a 
genome-wide quantitative trait locus (QTL) 
linkage scan.
Methods
Study population. From 1989 to 1991, all men 
and women 45–74 years of age from selected 
communities in Arizona and Oklahoma were 
invited to participate in the SHS (Lee et al. 
1990). In North and South Dakota, a clus-
ter sampling technique was used. Of all the 
individuals invited, 62% agreed to participate. 
Participants were similar to non participants 
in age, body mass index (BMI), and self-re-
ported frequency of diabetes. Women were 
more likely to participate than men. Starting in 
1998, the Strong Heart Family Study (SHFS) 
recruited persons who were ≥ 18 years of age 
and extended family members of the original 
SHS participants to participate in a study of 
the genes that contribute to cardiometabolic 
risk in American Indian populations (North 
et al. 2003). For the SHFS, families who had at 
least five living siblings, including three original 
SHS participants, were invited; and parents, 
spouses, offspring, spouses of offspring, and 
grand children were enrolled to build extended 
pedigrees. The SHFS genotyped genome-wide 
STR markers in all participants.
Urine metals, including the arsenic spe-
cies inorganic arsenic, MMA and DMA, 
were measured in 3,974 individual persons 
who participated in the SHS baseline visit 
(1989–1991) (Scheer et al. 2012). For the 
present analy sis, we excluded 1 participant 
who was missing total arsenic, and 1 partici-
pant missing inorganic arsenic concentrations. 
We further excluded 222 participants whose 
%iAs, %MMA, or %DMA were below the 
limit of detection. We also excluded 5 par-
ticipants who were missing information on 
smoking, 9 participants missing information 
on alcohol consumption, 16 participants 
missing BMI measurement, 1 participant 
missing level-of-education information, and 
5 participants missing urine creatinine, leav-
ing a sample size of 3,714 SHS participants. 
Among those, 2,907 SHS participants had 
at least 1 relative within the cohort, allowing 
heritability analy sis and 487 were also SHFS 
participants with STR marker information for 
the linkage analy sis.
The 13 participating tribes, the Indian 
Health Service (IHS) Institutional Review 
Board (IRB), and the IRBs of the partici-
pating institutions approved the SHS and 
SHFS protocol and consent forms. All partici-
pants provided written and oral informed 
consent at enrollment into the SHS. The 
present heritability and linkage study was 
covered by the original SHS consent form 
because arsenic is a potential cardiovascular 
risk factor. In addition, the present study was 
specifically approved by the SHS Publications 
and Presentations Committee and by the par-
ticipating tribes.
Urine arsenic. Spot urine samples were col-
lected in 1989–1991, frozen within 1–2 hr of 
collection, and stored at –80ºC at the Penn 
Medical Laboratory, MedStar Health Research 
Institute (Hyattsville, MD, and Washington, 
DC, USA) (Lee et al. 1990). In 2009, up to 
1.0 mL of urine from each participant was 
transported on dry ice to the Trace Element 
Laboratory of the Institute of Chemistry–
Analytical Chemistry, Karl-Franzens University 
(Graz, Austria). There, total arsenic concentra-
tions in the urine samples were measured by 
inductively coupled plasma mass spectrom-
etry (ICPMS) (Agilent model 7700× ICPMS; 
Agilent Technologies, Waldbronn, Germany), 
and arsenic species were determined by high 
performance liquid chromatography (HPLC; 
Agilent model 1100) coupled to ICPMS and 
served as the arsenic selective detector (HPLC/
ICPMS). The analytical methods used to 
determine urine arsenic concentrations have 
been described in detail (Scheer et al. 2012). 
The limits of detection were 0.2 µg/L for total 
arsenic, and 0.1 µg/L for iAs, MMA, DMA, 
and for arsenobetaine plus other cations. 
Participants with iAs, MMA, and DMA below 
the limits of detection (5.3% for iAs, 0.7% for 
MMA, 0.03% for DMA) were excluded from 
this analy sis because it is not possible to evalu-
ate arsenic metabolism with undetectable urine 
arsenic biomarkers. An in-house reference urine 
and the NIES No. 18 Human Urine from the 
National Institute for Environmental Studies 
(Ibaraki, Japan) were analyzed together with 
the samples. The inter assay coefficients of vari-
ation for the in-house reference urine for total 
arsenic, iAs, MMA, DMA, and arsenobetaine 
plus other cations were 4.4%, 6.0%, 6.5%, 
5.9%, and 6.5%, respectively.
Urine arsenic data were transmitted to the 
Texas Biomedical Research Institute (previ-
ously known as Southwest Foundation for 
Biomedical Research) where they were trans-
ferred to the pedigree data management sys-
tem PEDSYS (Dyke 1999).
Demographic and lifestyle assessment. 
Baseline sociodemographic, lifestyle, and 
anthropometric information was obtained 
through interview and physical exami-
nation conducted by trained nurses and 
medical assistants (Lee et al. 1990). The stan-
dardized in-person questionnaire included 
socio demographic data (age, sex, education) 
and smoking status (never, current, former). 
Body mass index (BMI) was estimated by 
dividing measured weight in kilograms by 
measured height in meters squared.
Short tandem repeat markers. DNA 
from white cells was isolated and stored at 
the Texas Biomedical Research Institute. 
We genotyped nearly 400 STR markers, 
spaced, on average 10 cM (centi morgans) 
apart (range, 2.4–24.1 cM) [For details, see 
Supplemental Material, Table S3 (http://
dx.doi.org/10.1289/ehp.1205305)], using 
ABI PRISM Linkage Mapping Set-MD10 
version 2.5 (Applied Biosystems, Foster City, 
CA, USA). Individual polymerase chain reac-
tion (PCR) products were loaded into an 
ABI PRISM 377 Genetic Analyzer for laser-
based automated genotyping. Genotypes 
were assigned using the Genotyper software 
system (Applied Biosystems). Pedigree rela-
tionships were verified and likely genotyping 
errors were detected using PREST software 
version 3.02 (Pedigree Relationship Statistical 
Tests, http://utstat.toronto.edu/sun/Software/
Prest/prest3.02/) (McPeek and Sun 2000; 
Sun et al. 2002) and SimWalk2 (Sobel et al. 
2002). Mendelian inconsistencies and unlikely 
double recombinants in marker genotypes 
were removed with an overall blanking rate 
of < 1% in the total study population. The 
average heterozygosity was 0.69 for Arizona, 
0.74 for Oklahoma, and 0.76 for North and 
South Dakota.
Statistical analy sis. Descriptive analy sis. 
To evaluate urine arsenic methylation and 
excretion patterns, we computed the propor-
tions of iAs, MMA, and DMA by dividing 
the concentration of each species by the sum 
of all three species and multiplying by 100, 
yielding %iAs, %MMA, and %DMA. The 
median [interquartile range (IQR)] percent-
ages of urine arsenic species were reported for 
the overall population and according to age 
(≤ 55 years, > 55 years), sex (men, women), 
education (< 12 years completed, ≥ 12 years 
completed), BMI (< 30 kg/m2, ≥ 30 kg/m2), 
smoking (never, former, current), alcohol con-
sumption (never, former, current), and study 
region (Arizona, Oklahoma, and North and 
South Dakota).
Heritability. We estimated the herita-
bility of %iAs, %MMA, and %DMA using 
a general pedigree variance components 
decomposition-based method as conducted 
by the software Sequential Oligogenic Linkage 
Analysis Routines (SOLAR) version 4.4.0 
(Almasy et al. 2012). For a detailed descrip-
tion of the statistical methods used to esti-
mate herita bility, see Supplemental Material, 
pp.  2–3 (http://dx.doi .org/10.1289/
ehp.1205305). In brief, SOLAR incorporates 
the information contained in participant pedi-
grees to obtain maximum likelihood estimates 
for the proportion of unexplained variance due 
to additive genetic effects from polygenes (σ2g) 
and the proportion of variance due to unmea-
sured environmental covariates, measurement 
error, and nonadditive genetic effects (σ2e). 
Heritability (h2) is defined as the proportion 
of unexplained variance in the observed dis-
tribution of the percent of each urine arsenic 
species that is attributable to additive genetic 
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effects, or h2 = σ2g/(σ2g + σ2e). The p-values 
for h2 are computed from a likelihood ratio 
test comparing the model in which the h2 
component of the unexplained variance is esti-
mated to a model in which h2 is constrained 
to be zero, following a 1/2:1/2 mixture of chi-
square distributions with 1 degree of freedom 
(df) and a point mass at zero (Amos 1994).
Initially, the percentage of each urine 
arsenic species was converted to an odds and 
introduced in a linear variance component 
model as a logit-transformed dependent vari-
able adjusted for age, sex, age2, age × sex 
and age2 × sex, education (< 12 years of 
education, ≥ 12 years of education), BMI 
(< 30 kg/m2, ≥ 30 kg/m2), smoking status 
(never, former, current smokers), alcohol 
drinking status (never, former, current drink-
ers), region (Arizona, Oklahoma, and North 
and South Dakota), and total urine arsenic 
concentrations. To reduce kurtosis, residuals 
from the linear variance component model 
were transformed using an inverse Gaussian 
transformation and introduced as dependent 
variables in a second-stage variance component 
linear regression with no covariables. A house-
hold component of the variance was explored 
to account for “shared environment” among 
relatives living in the same household, but 
household component was not retained in the 
final model because it did not influence the 
heritability estimates (data not shown). We 
performed heritability analy sis for the popula-
tion as a whole, and stratified by region.
Linkage scan. We implemented a multi-
point QTL linkage analy sis based on variance 
components decomposition-based methods in 
SOLAR version 4.4.0 (Almasy and Blangero 
1998; Almasy et al. 2012), building on the 
heritability models described above by includ-
ing additional variance components for QTLs 
based on multipoint identity-by-descent (IBD) 
matrices [for details on model formulation, 
see Supplemental Material, pp, 2–3 (http://
dx.doi.org/10.1289/ehp.1205305)]. We com-
puted multipoint IBD matrices using the soft-
ware Loki (Heath 1997; Heath et al. 1997) 
by using STR marker map positions obtained 
based on the DeCode map (NHLBI 2012). At 
each chromosomal location, SOLAR conducts 
likelihood ratio tests comparing a model that 
estimates the unexplained variance attribut-
able to a potential QTL versus a model that 
constrains the unexplained variance attribut-
able to the potential QTL to be equal to zero. 
The tests at each chromosomal location are 
reported as LOD [logarithm (to the base of 
10) of the odds] scores in favor of genetic link-
age with a QTL. LOD scores of 1.9 and 3.3 
are considered suggestive and significant evi-
dence, respectively, for a QTL (Lander and 
Kruglyak 1995). To evaluate whether the link-
age findings may have been due to chance, 
we conducted an adjustment analy sis in order 
to calculate an empirical LOD score for each 
urine arsenic metabolite. The empirical LOD 
scores were computed by multiplying the origi-
nal LOD scores with a correction constant. 
The correction constant is calculated when a 
fully informative marker, not associated with 
the phenotype, is simulated and goes through 
approximately 10,000 replicates, IBDs are cal-
culated for this marker and the LOD score is 
computed for linkage of this phenotype to this 
marker. In this analy sis, if the original LOD 
score is similar to the adjusted LOD score, 
then the possibility of findings being due to 
chance alone is low.
Sensitivity analyses. Several sensitivity 
analyses were conducted for both the heritabil-
ity and the linkage scan. First, we adjusted for 
BMI as continuous rather than categorical. 
Second, we added an interaction term for BMI 
(categorical) × sex. Third, we further adjusted 
for urine selenium. Fourth, we accounted for 
urine dilution by adjusting for urine creati-
nine rather than by dividing by urine creati-
nine. Last, we repeated the analyses without 
accounting for urine dilution. The heritability 
and linkage scan analyses remained unchanged 
(data not shown).
Results
Descriptive analy sis. Median (IQR) total 
urine arsenic concentrations were 18.5 (12.5–
27.2) µg/g in Arizona, 8.2 (5.6–12.9) µg/g 
in Oklahoma, and 12.5 (8.2–18.9) µg/g in 
North and South Dakota (Table 1). The 
median (IQR) urine arsenobetaine concentra-
tion was 0.7 (0.4–1.6) µg/g, consistent with 
the low self-reported seafood consumption in 
the study population. The median (IQR) for 
%iAs, %MMA, and %DMA were 7.7 (5.4–
10.7)%, 13.6 (10.5–17.1)%, and 78.4 (72.5–
83.1)%, respectively, with no differences by 
total urine arsenic concentrations above and 
below the median (Table 2). The %MMA was 
higher in men compared with women, in par-
ticipants from North and South Dakota com-
pared with other regions, in participants with 
BMI < 30 kg/m2 compared with ≥ 30 kg/m2, 
and current smokers compared with non-
smokers (Table 2). Urine arsenic levels and 
participant characteristics in the subsample of 
487 participants with information for the link-
age analy sis were similar to those of the larger 
study sample included in the heritability analy-
sis [see Supplemental Material, Tables S1 and 
S2 (http://dx.doi.org/10.1289/ehp.1205305)]. 
Total urine arsenic concentrations in the 
full study sample were weakly correlated 
with %iAs and %MMA, but not correlated 
with %DMA (see Supplemental Material, 
Figure S1). The %iAs and %MMA were mod-
erately positively correlated (Spearman cor-
relation coefficient 0.46). The %DMA was 
strongly negatively correlated with %iAs and 
%MMA (Spearman correlation coefficients 
–0.81 and –0.87, respectively).
Heritability. After accounting for age, sex, 
education, smoking, alcohol consumption, 
BMI, and region, the estimated residual heri-
tability was 53% for %iAs, 50% for %MMA, 
and 59% for %DMA, with similar estimates 
when stratified by study region (Table 3).
Linkage scan. We found suggestive evi-
dence in favor of QTLs for %iAs on chro-
mosomes 5 (LOD = 2.03 at 39 cM, marker 
D5S416), 9 (LOD = 2.05 at 51 cM, between 
markers D9S171 and D9S161), and 11 
(LOD = 1.91 at 9 cM, marker D11S1338); and 
for %MMA on chromosome 9 (LOD = 2.10 
at 162 cM, marker D9S158) [Figure 1 and 
see also Supplemental Material, Figure S2 
(http://dx.doi.org/10.1289/ehp.1205305)]. 
The correction constants for computing 
empirical LOD scores were 0.99 for %iAs, 
0.87 for %MMA, and 0.92 for %DMA. Thus, 
the adjusted LOD scores for %iAs remained 
very similar to the original scores (2.01, 2.03, 
and 1.89 for %iAs on chromosomes 5, 9, and 
11, respectively), whereas the adjusted LOD 
for %MMA on chromosome 9 decreased to 
a greater extent (adjusted LOD = 1.83). A 
peak for %DMA on chromosome 10 within 
2 Mb (megabases ) of AS3MT did not reach the 
level of suggestive evidence in favor of QTLs 
(LOD = 1.80 at 125 cM, between markers 
Table 1. Characteristics of SHS participants having at least one relative within the cohort.
Arizona Oklahoma North/South Dakota Overall
Total (n) 1,259 1,139 509 2,907
Age (years) 55.4 ± 0.2 56.6 ± 0.2 56.0 ± 0.4 56.0 ± 0.1
Sex (% males) 36.2 (1.4) 43.7 (1.5) 43.8 (2.2) 40.5 (0.9)
Education (% < high school) 60.8 (1.4) 30.5 (1.4) 47.9 (2.2) 46.6 (0.9)
BMI (kg/m2) 36.5 ± 0.2 30.7 ± 0.2 29.9 ± 0.3 31.4 ± 0.1
Smoking status (%)
Former 35.1 (1.4) 36.1 (1.4) 30.5 (2.0) 35.3 (0.9)
Current 19.5 (1.1) 35.1 (1.4) 46.6 (2.2) 30.4 (0.9)
Current alcohol drinkers (%)
Former 39.6 (1.4) 45.4 (1.5) 38.2 (2.2) 41.7 (0.9)
Current 41.9 (1.4) 37.9 (1.4) 50.9 (2.2) 41.9 (0.9)
Total arsenic [median (IQR), μg/g] 18.5 (12.5–27.2) 8.2 (5.6–12.9) 12.5 (8.2–18.9) 12.9 (7.9–21.0)
Arsenobetaine [median (IQR), μg/g] 0.8 (0.5–1.7) 0.7 (0.4–1.8) 0.5 (0.3–1.0) 0.7 (0.4–1.6)
Urine selenium [median (IQR), μg/g] 48.0 (36.5–64.3) 42.2 (33.9–55.4) 63.7 (47.4–85.3) 47.7 (36.1–64.9)
Data are presented as percentage (SE) for categorical variables or mean ± SE for continuous variables.
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D10S192 and D10S597) (Figure 1; see also 
Supplemental Material, Figure S2).
In analyses stratified by geographic region, 
the peak in chromosome 5, the two peaks in 
chromosome 9, and the peak in chromosome 
10 were smaller but present in all three regions 
[see Supplemental Material, Figure S2 (http://
dx.doi.org/10.1289/ehp.1205305)]. There were 
also differences by region. In Oklahoma, there 
was suggestive evidence in favor of an addi-
tional QTL for %MMA on chromosome 18 
(LOD = 2.21 at 22 cM, markers D18S63 and 
D18S452) and for %DMA on chromosome 
19 (LOD = 2.29 at 79 cM, marker D19S902). 
In North and South Dakota there were sugges-
tive peaks for %MMA and %DMA on chro-
mosome 12 (LOD = 1.89 at 56 cM and 2.93 
at 61 cM, respectively, markers D12S345 and 
D12S85) and for %DMA on chromosome 16 
(LOD = 1.95, at 39 cM, marker D16S3103).
Discussion
This population-based study in American 
Indian communities from Arizona, Oklahoma, 
and North and South Dakota supports a 
genetic contribution to variability in the 
distribution of urine arsenic metabolites. 
The heritability of urine arsenic metabolites 
ranged between 50% for %MMA and 59% 
for %DMA, with no major differences by 
study region. Based on a QTL linkage scan in 
a subset of our study population, we identi-
fied several genetic loci that may contribute 
to the pattern of urine arsenic metabolites. 
The presence of multiple loci indicates that, 
as suspected, multiple genes may be involved. 
Our unbiased discovery approach identified 
potential areas of the genome that may be 
related to metabolic processes and excretion 
of arsenic species in urine. Several biologically 
plausible genes (Hernandez and Marcos 2008) 
were located in those areas, including three 
histone methyltransferases [PR domain zinc 
finger protein 9 (PRDM9) on chromosome 5, 
histone methyltransferase EHMT1 on chromo-
some 9, and ribosome RNA-processing pro-
tein 8 (RRP8) on chromosome 11] and one 
aquaglyceroporin, aquaglyceropin 3 (AQP3) 
on chromosome 9. The peak for %DMA on 
chromosome 10 was within 2 Mb of AS3MT 
but did not reach the level of suggestive evi-
dence. Larger linkage studies and fine mapping 
are needed to confirm the relevance of these 
findings and to identify the genes and variants 
related to arsenic methylation patterns in urine.
In human populations, arsenic metabolism 
is commonly studied by measuring the rela-
tive proportion of inorganic and methyla ted 
arsenic metabolites in urine (Vahter 2000). 
Determinants of arsenic metabolism include 
sex, smoking, alcohol intake, nutritional status, 
BMI, and race/ethnicity (Gamble et al. 2005; 
Gomez-Rubio et al. 2011, 2012; Hopenhayn-
Rich et al. 1996a; Hsueh et al. 2003; Navas-
Acien et al. 2009; Steinmaus et al. 2005). 
Men, smokers, people who drink alcohol, and 
people with nutritional deficiencies have higher 
%MMA and lower %DMA in urine (Gamble 
et al. 2005; Hsueh et al. 2003; Navas-Acien 
et al. 2009). Nutritional deficiencies, especially 
low folate and selenium levels, have been asso-
ciated with lower arsenic methylation capacity 
Table 2. Median (IQR) of percentage urine arsenic species in the SHS participants having at least one 
relative within the cohort.
n %iAs %MMA %DMA
Overall 2,907 7.7 (5.4–10.7) 13.6 (10.5–17.1) 78.4 (72.5–83.1)
Age (years)
≤ 55 1,481 8.3 (5.8–11.2) 13.6 (10.4–17.2) 77.8 (72.1–82.8)
> 55 1,426 7.2 (5.1–10.1) 13.6 (10.6–17.0) 79.1 (73.0–83.5)
Sex
Men 1,177 9.2 (6.4–12.7) 15.4 (12.1–18.9) 75.0 (68.8–80.7)
Women 1,730 6.9 (4.9–9.4) 12.6 (9.6–15.7) 80.2 (75.3–84.4)
Study region
Arizona 1,259 8.6 (6.1–11.5) 13.3 (10.4–16.4) 78.0 (72.6–82.5)
Oklahoma 1,139 6.6 (4.6–9.3) 13.3 (10.2–16.8) 79.6 (74.0–84.3)
North and South Dakota 509 8.1 (5.9–11.5) 15.3 (11.9–19.4) 76.5 (69.2–81.6)
Education (years)a
< 12 1,551 7.4 (5.3–10.6) 13.5 (10.3–16.9) 78.7 (72.7–83.5)
≥ 12 1,356 8.1 (5.7–11.0) 13.6 (10.8–17.3) 78.2 (72.2–82.6)
BMI (kg/m2)b
< 30 1,329 8.3 (5.7–11.4) 15.2 (11.8–18.6) 76.4 (70.2–81.3)
≥ 30 1,578 7.3 (5.3–10.1) 12.5 (9.7–15.6) 79.9 (74.5–84.2)
Smoking
Never 998 7.3 (5.3–10.0) 13.2 (10.0–16.0) 79.4 (74.2–83.7)
Former 1,026 7.6 (5.3–10.5) 13.3 (10.4–16.9) 78.8 (72.9–83.7)
Current 883 8.6 (5.8–11.8) 14.8 (11.2–18.6) 76.6 (70.1–81.8)
Alcohol drinking
Never 476 7.1 (5.2–9.5) 13.4 (10.5–16.3) 79.6 (74.0–83.4)
Former 1,212 7.5 (5.3–10.7) 13.6 (10.5–17.0) 78.4 (72.6–83.5)
Current 1,219 8.2 (5.7–11.2) 13.7 (10.5–17.5) 77.8 (71.7–82.8)
Total arsenic (µg/g)c
< 12.9 1,452 7.3 (5.2–10.1) 14.3 (11.2–17.8) 78.2 (72.3–82.7)
≥ 12.9 1,455 8.2 (5.8–11.4) 13.0 (9.9–16.4) 78.8 (72.7–83.5)
Arsenobetaine (µg/g)c
< 0.7 1,448 8.0 (5.7–10.9) 14.3 (11.0–17.6) 77.6 (71.9–82.2)
≥ 0.7 1,459 7.5 (5.1–10.5) 13.1 (10.0–16.5) 79.4 (73.5–83.9)
Urine selenium (µg/g)c
< 47.7 1,452 7.8 (5.4–11.0) 14.2 (10.9–17.7) 77.7 (71.6–82.6)
≥ 47.7 1,455 7.7 (5.5–10.5) 13.1 (10.1–16.3) 79.1 (73.5–83.5)
aFor education we selected a cut-off of 12 years, consistent with the completion of high school. bFor BMI we selected a 
cut-off of 30 kg/m2, commonly used to classify individuals as obese and nonobese. cThe cut-off is the median.
Table 3. Heritability of urine arsenic metabolites in SHS participants having at least one relative within 
the original cohort.
Heritability (SE) p-Value
Percent variance explained 
by covariables
Overall (n = 2,907)
%iAs 0.53 (0.07) < 0.001 15.5%
%MMA 0.50 (0.07) < 0.001 19.4%
%DMA 0.59 (0.06) < 0.001 20.4%
Arizona (n = 1,259)
%iAs 0.46 (0.12) < 0.001 11.8%
%MMA 0.51 (0.12) < 0.001 15.1%
%DMA 0.60 (0.11) < 0.001 16.4%
Oklahoma (n = 1,139)
%iAs 0.50 (0.12) < 0.001 10.6%
% MA 0.53 (0.11) < 0.001 22.6%
%DMA 0.62 (0.10) < 0.001 20.9%
North and South Dakota (n = 509)
%iAs 0.60 (0.11) < 0.001 19.6%
%MMA 0.36 (0.12) 0.001 19.9%
%DMA 0.55 (0.11) < 0.001 23.4%
Adjusted for age, age2, sex, age × sex, age2 × sex, smoking status (never, former, current), education (< 12 years, 
≥12 years), BMI (< 30 kg/m2, ≥ 30 kg/m2), alcohol status (never, former, current), location (Arizona, Oklahoma, North and 
South Dakota), and total arsenic (log µg/g). Residual kurtosis ranged from –0.14 to –0.04. The number of pair relationships 
in the overall sample is distributed as follows: 93 parent–offspring; 1,142 siblings; 271 avuncular; 73 half siblings; 3 double 
first cousins; 4 grand avuncular; 32 half avuncular; 172 first cousins; 9 half first cousins and half second cousins; 13 first 
cousins once removed (1 rem); 9 half first cousins; 9 half first cousins, 1 rem, and half second cousins, 1 rem.
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and could play an important role in arsenic 
toxicity (Christian et al. 2006; Gamble et al. 
2006; Heck et al. 2007; Hsueh et al. 2003). 
On the other hand, obesity and indigenous 
American ancestry have been associated with 
increased %DMA in urine (Gomez-Rubio 
et al. 2011, 2012). Studies on the role of arse-
nic exposure levels in arsenic metabolism have 
been inconsistent. Some studies have shown 
no relationship between exposure levels and 
methylation patterns (Hopenhayn-Rich et al. 
1996a, 1996b). Others have found increasing 
arsenic levels in drinking water were associ-
ated with higher %MMA and lower %DMA 
in urine (Heck et al. 2007; Lindberg et al. 
2008). In our study, at low-to-moderate arse-
nic exposure levels, the distribution of arsenic 
species was similar for participants with urine 
total arsenic concentrations below and above 
the median. Nongenetic factors could result in 
false positives in a linkage study if they mimic 
Mendelian patterns, an unlikely occurrence. 
Regarding indigenous American ancestry, our 
findings are consistent with those from Andean 
(Engstrom et al. 2010; Hopenhayn-Rich et al. 
1996b; Vahter et al. 1995) and Northwest 
Mexican (Gomez-Rubio et al. 2012) com-
munities characterized by higher %DMA in 
urine compared with populations in Europe 
and Asia (Chiou et al. 1997; Gamble et al. 
2005; Kile et al. 2011; Lindberg et al. 2007). 
The different arsenic methylation profile in 
American Indian populations could be partly 
genetically determined.
A number of studies have estimated asso-
ciations of genetic polymorphisms with arsenic 
metabolism in different populations (Chiou 
et al. 1997; Engstrom et al. 2011; Gomez-
Rubio et al. 2010; Hernandez and Marcos 
2008; Hernandez et al. 2008; Lindberg et al. 
2007; McCarty et al. 2007; Meza et al. 2005; 
Schlawicke et al. 2007, 2009; Vahter 2000), as 
measured by the relative distribution of inor-
ganic and methylated metabolites in urine. So 
far, those studies have evaluated only a limited 
number of polymorphisms, and no genome-
wide scans, using either SNPs or microsatellite 
markers (STR), are available. Polymorphisms 
in AS3MT have been associated with urine 
arsenic metabolites in populations in Argentina 
(Engstrom et al. 2011; Schlawicke et al. 
Figure 1. LOD scores on chromosomes 5, 9, 10, and 11 for urine arsenic metabolites in SHS participants with STR marker genotype (n = 487). Models were 
adjusted for age, age2, sex, age × sex, age2 × sex, smoking status (never, former, current), education (< 12 years, ≥12 years), alcohol drinking status (never, for-
mer, current), BMI (< 30 kg/m2, ≥ 30 kg/m2), location (Arizona, Oklahoma, North and South Dakota), and total arsenic (log µg/g). Residual kurtosis was –0.14 for 
%iAs, %MMA, and %DMA. The number of pair relationships among the 487 participants was distributed as follows: 33 parent–offspring; 268 siblings; 93 avuncu-
lar; 36 half siblings; 2 double first cousins; 3 grand avuncular; 19 half avuncular; 87 first cousins; 9 half first cousins and half second cousins; 8 first cousins once 
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2007, 2009), Chile (Hernandez et al. 2008), 
Mexico (Gomez-Rubio et al. 2010; Meza et al. 
2005), Bangladesh (Engstrom et al. 2011), 
and Central Europe (Lindberg et al. 2007). 
Moreover, the functional relevance of AS3MT 
is well established (Chen et al. 2011; Drobna 
et al. 2006; Thomas et al. 2004; Wood et al. 
2006). In our study, the peak on chromo-
some 10 close to AS3MT did not reach the 
level of suggestive evidence for linkage, and 
larger linkage studies within the overall SHFS 
population, as well as association studies, are 
needed to further evaluate the relevance of 
AS3MT in our population. Recently, another 
methyltransferase, N-6 adenine-specific DNA 
methyl transferase (N6AMT1), was shown 
in vitro to methylate arsenic in human urothe-
lial cells (Ren et al. 2011). However, there was 
no evidence in our linkage scan of a peak in 
the vicinity of this gene, which is located on 
chromosome 21. Some of the peaks in our 
study, however, were within 2 Mb of histone 
methyltransferases (PRDM9, EHMT1 and 
RRP8). In Oklahoma, the peak for %MMA 
on chromosome 18 was close to RNA methyl-
transferase (RNMT); in North and South 
Dakota, the peaks for %MMA and %DMA 
on chromosome 12 were close to methyltrans-
ferase-like 20 (METTL20). The possible role 
of these methylatransferases in arsenic metabo-
lism has not been previously evaluated. The 
localization of QTLs in gene regions encom-
passing several histone methyltransferases is 
interesting given the increasingly recognized 
connections between arsenic and epigenetic 
modifications including histone methyla-
tion and acetylation (Arita and Costa, 2009; 
Baccarelli and Bollati, 2009; Hou et al. 2012; 
Martinez-Zamudio and Ha 2011).
In addition to methyltransferases, other 
genes have been suggested to play a role in 
arsenic metabolism, including gluta thione 
and glutathione transferase genes, one-
carbon metabolism and reduction genes, 
purine nucleo side phosphorylase genes, and 
transporter genes (Hernandez and Marcos 
2008). Transporter genes could be important 
for the absorption and excretion of inorganic 
arsenic species (Hernandez and Marcos 2008). 
In our study, we found a peak for %iAs within 
2 Mb of AQP3 on chromosome 9. In vitro 
studies have shown that uptake of inorganic 
trivalent arsenicals is facilitated by several AQP 
cell membrane proteins (Calatayud et al. 2012; 
Liu et al. 2002, 2004). In vivo, AQP9-null 
mice had reduced arsenic clearance (Carbrey 
et al. 2009). In humans, polymorphisms in 
AQP3 have recently been related to increased 
bladder cancer risk in individuals from New 
Hampshire who were exposed to arsenic in 
drinking water (Lesseur et al. 2012). Human 
studies are needed to evaluate the association 
of aquaglyceroporin polymorphisms with 
urine arsenic metabolites.
Our study has a number of limitations. 
First, the sample size for the linkage scan was 
small, particularly when stratified by region. 
Although the results of the heritability analyses 
were similar across the three regions, a larger 
study sample would be needed to confirm the 
consistency of the QTL linkage scan across 
regions and to evaluate gene × environment 
interactions by other characteristics such as 
arsenic exposure and sex. Ongoing arsenic 
speciation analy sis in all SHFS participants 
and additional genetic analy sis of a panel of 
polymorphisms in candidate genes potentially 
related to arsenic metabolism, including those 
informed by the present study, will allow us 
to determine if the linkages observed remain 
in the larger population as well as to study 
potential gene × environment interactions for 
arsenic related health effects.
A second limitation is that only one 
measurement of urine arsenic was available, 
although we confirmed the relative constancy 
of urine arsenic methylation patterns over a 
10-year period in a pilot study of the same 
population (Navas-Acien et al. 2009). In addi-
tion, we could not determine if the loci asso-
ciated with arsenic methylation patterns in 
urine were also associated with methylation 
patterns in other tissues or fluids, for instance, 
blood. Also, as in other linkage scans, peaks 
included relatively large genomic regions and 
substantial uncertainty remains regarding the 
specific genes involved. Finally, our popula-
tion was exposed to low-to-moderate arsenic 
levels (from < 10 to > 50 µg/L in drinking 
water) and the relevance of the findings at dif-
ferent exposure levels is unknown. Strengths 
of the study include the availability of highly 
informative complex pedigrees for evaluat-
ing genetic determinants, the large sample 
size for the heritability analy sis, and the high-
quality standardized protocols used to recruit 
participants, conduct interviews and physical 
examinations, collect biological specimens, 
and perform laboratory analyses to measure 
arsenic species using highly sensitive methods 
(Lee et al. 1990; Scheer et al. 2012).
In conclusion, our heritability analy sis and 
preliminary genome-wide linkage scan supports 
the hypothesis that genetic variation across the 
genome contributes substantially to the vari-
ability of urine arsenic methylation patterns 
in urine. The discovery and characterization 
of genes involved in arsenic metabolism is an 
important area of research as arsenic methyla-
tion patterns in urine have been related to can-
cer and cardiovascular disease risk (Chen et al. 
2003; Del Razo et al. 1997; Hsueh et al. 1997; 
Kile et al. 2011; Steinmaus et al. 2006; Wu 
et al. 2006; Yu et al. 2000). Additional epide-
miologic and experimental studies are needed 
to identify specific variants that are related to 
arsenic metabolism, confirm the findings in 
different populations, evaluate the function 
of potentially novel candidate genes such as 
histone methyltransferases and aquaglycero-
porins, and evaluate the role of arsenic metabo-
lism genes and of arsenic-gene interactions in 
arsenic- related toxicity and health effects.
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